Tiago Fleming Outeiro

Summary

Affiliation: Faculdade de Medicina
Country: Portugal

Publications

  1. pmc Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies
    Tiago Fleming Outeiro
    Instituto de Medicina Molecular, Instituto de Fisiologia, Faculdade de Medicina, Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Perspect Medicin Chem 2:41-9. 2008
  2. pmc Formation of toxic oligomeric alpha-synuclein species in living cells
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH Harvard Medical School, Charlestown, Massachusetts, United States of America
    PLoS ONE 3:e1867. 2008
  3. ncbi request reprint Current and future therapeutic strategies for Parkinson's disease
    Tiago Fleming Outeiro
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Curr Pharm Des 15:3968-76. 2009
  4. pmc Dopamine-induced conformational changes in alpha-synuclein
    Tiago F Outeiro
    MassGeneral Institute for Neurodegenerative Disease, Alzheimer Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
    PLoS ONE 4:e6906. 2009
  5. ncbi request reprint Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
  6. ncbi request reprint PLK2 modulates α-synuclein aggregation in yeast and mammalian cells
    Elisa Basso
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisbon, Portugal
    Mol Neurobiol 48:854-62. 2013
  7. pmc Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy
    Susana Goncalves
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Mol Neurobiol 47:1081-92. 2013
  8. ncbi request reprint Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models
    Tiago Fleming Outeiro
    Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 3300, 16th St, Charlestown, MA 02129 4404, USA
    Biochem Biophys Res Commun 357:596-602. 2007
  9. doi request reprint Imaging protein oligomerization in neurodegeneration using bimolecular fluorescence complementation
    Federico Herrera
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    Methods Enzymol 506:157-74. 2012
  10. doi request reprint Epigenetics in Parkinson's and Alzheimer's diseases
    Sueli Marques
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av Prof Egas Moniz, 1649 028, Lisboa, Portugal
    Subcell Biochem 61:507-25. 2013

Collaborators

Detail Information

Publications31

  1. pmc Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies
    Tiago Fleming Outeiro
    Instituto de Medicina Molecular, Instituto de Fisiologia, Faculdade de Medicina, Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Perspect Medicin Chem 2:41-9. 2008
    ..The therapeutic potential of small molecule modulators of oligomer formation demands further exploration and validation in cellular and animal disease models in order to accelerate human drug development...
  2. pmc Formation of toxic oligomeric alpha-synuclein species in living cells
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH Harvard Medical School, Charlestown, Massachusetts, United States of America
    PLoS ONE 3:e1867. 2008
    ..However, to date, oligomeric species have not been identified in living cells...
  3. ncbi request reprint Current and future therapeutic strategies for Parkinson's disease
    Tiago Fleming Outeiro
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Curr Pharm Des 15:3968-76. 2009
    ..The therapeutic potential of small molecule modulators of oligomer formation demands further exploration and validation in cellular and animal disease models in order to accelerate human drug development...
  4. pmc Dopamine-induced conformational changes in alpha-synuclein
    Tiago F Outeiro
    MassGeneral Institute for Neurodegenerative Disease, Alzheimer Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
    PLoS ONE 4:e6906. 2009
    ..A number of in vitro studies showed that dopamine can modulate the aggregation of alpha-synuclein by inhibiting the formation of or by disaggregating amyloid fibrils [5], [6], [7]...
  5. ncbi request reprint Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
    ..Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging...
  6. ncbi request reprint PLK2 modulates α-synuclein aggregation in yeast and mammalian cells
    Elisa Basso
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisbon, Portugal
    Mol Neurobiol 48:854-62. 2013
    ..Our study supports a role for PLK2 in the generation of aSyn inclusions by a mechanism that does not depend directly on serine 129 phosphorylation...
  7. pmc Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy
    Susana Goncalves
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Mol Neurobiol 47:1081-92. 2013
    ..Finally, we found that the molecular chaperone HSP70 accelerates the entry of aSyn into the nuclear compartment...
  8. ncbi request reprint Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models
    Tiago Fleming Outeiro
    Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 3300, 16th St, Charlestown, MA 02129 4404, USA
    Biochem Biophys Res Commun 357:596-602. 2007
    ..Further, our results suggest a rationale for the development of highly potent, bio-available, brain-penetrable PARP-1 inhibitors to provide therapeutic benefits for Parkinson's patients...
  9. doi request reprint Imaging protein oligomerization in neurodegeneration using bimolecular fluorescence complementation
    Federico Herrera
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    Methods Enzymol 506:157-74. 2012
    ..These systems could constitute powerful tools for the identification of genetic and pharmacological modifiers of protein misfolding and aggregation...
  10. doi request reprint Epigenetics in Parkinson's and Alzheimer's diseases
    Sueli Marques
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av Prof Egas Moniz, 1649 028, Lisboa, Portugal
    Subcell Biochem 61:507-25. 2013
    ..This chapter will discusses the role of epigenetics in AD and PD...
  11. pmc The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation
    Teresa Faria Pais
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    EMBO J 32:2603-16. 2013
    ..Our data uncover a novel role for SIRT2 opening new perspectives for therapeutic intervention in neuroinflammatory disorders. ..
  12. pmc Impaired proteostasis contributes to renal tubular dysgenesis
    Rita Machado de Oliveira
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    PLoS ONE 6:e20854. 2011
    ..In addition, we found that temperature shifting causes the ACE Q1069R protein to be secreted in an active state, suggesting that the mutation does not affect the enzyme's catalytic properties...
  13. ncbi request reprint Sirtuins: common targets in aging and in neurodegeneration
    Rita Machado de Oliveira
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Curr Drug Targets 11:1270-80. 2010
    ..Here, we review how sirtuins contribute for aging and, in particular, for neurodegeneration and how they are becoming attractive targets for therapeutic intervention...
  14. ncbi request reprint Mechanisms of disease II: cellular protein quality control
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, Charlestown, MA 02129, USA
    Semin Pediatr Neurol 14:15-25. 2007
    ..A detailed understanding of how the cellular quality control systems relate to neurodegeneration might lead to the development of novel therapeutic approaches for disorders associated with protein misfolding and aggregation...
  15. pmc Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, Charlestown, MA 02129, USA
    Biochem Biophys Res Commun 351:631-8. 2006
    ..In addition, intracellular inclusions were immunopositive for endogenous Hsp27, and overexpression of this protein reduced aSyn aggregation in a cell culture model...
  16. doi request reprint Therapeutic role of sirtuins in neurodegenerative disease
    Tiago Fleming Outeiro
    Cellular and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Instituto de Fisiologia, Faculdade de Medicina da Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Biochim Biophys Acta 1782:363-9. 2008
    ..Here, we review current data which support the putative therapeutic roles of sirtuin in aging and in neurodegenerative diseases and the feasibility of the development of sirtuin-based therapies...
  17. pmc LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models
    Patrícia Silva Guerreiro
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisbon 04250, Portugal
    J Mol Med (Berl) 91:513-22. 2013
    ....
  18. pmc SIRT2 as a Therapeutic Target for Age-Related Disorders
    Rita Machado de Oliveira
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular Lisboa, Portugal
    Front Pharmacol 3:82. 2012
    ..This review summarizes the main scientific advances on SIRT2 protein biology and explores its potential as a therapeutic target for treatment of age-related disorders...
  19. pmc Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease
    Sandra Tenreiro
    Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
    PLoS Genet 10:e1004302. 2014
    ....
  20. doi request reprint Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease
    Tiago Martins Rodrigues
    Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
    Drugs Aging 31:239-61. 2014
    ..In this article, we review the current status of the potential relevance of NTFs for treating PD, taking into consideration experimental evidence, human observational studies, and data from clinical trials. ..
  21. ncbi request reprint Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation
    Maria José Diógenes
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Ed Egas Moniz, 1649 028 Lisboa, Portugal
    J Neurosci 32:11750-62. 2012
    ..Our novel findings provide mechanistic insight on how a-syn oligomers may trigger neuronal dysfunction and toxicity in PD and other synucleinopathies...
  22. doi request reprint α-Synuclein modifies huntingtin aggregation in living cells
    Federico Herrera
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    FEBS Lett 586:7-12. 2012
    ..Our results support the idea that co-aggregation of aggregation-prone proteins can contribute to the histopathology of neurodegenerative disorders...
  23. doi request reprint Modulating Alzheimer's disease through caffeine: a putative link to epigenetics
    Sueli Marques
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    J Alzheimers Dis 24:161-71. 2011
    ..In addition, we speculate on the potential of caffeine as an epigenetic modulator and the consequences it might have for preventive and therapeutic applications of caffeine in AD...
  24. ncbi request reprint Neurotrophic factors as a protective strategy in Parkinson's disease
    Maria José Diógenes
    Institute of Pharmacology and Neurosciences, Faculty of Medicine, University of Lisbon, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    CNS Neurol Disord Drug Targets 9:754-63. 2010
    ..Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent...
  25. doi request reprint Simple is good: yeast models of neurodegeneration
    Sandra Tenreiro
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    FEMS Yeast Res 10:970-9. 2010
    ..Here, we review the recent contributions of this simple, but powerful model organism toward our understanding of neurodegeneration...
  26. pmc Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18 505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
    ....
  27. ncbi request reprint Yeast as a drug discovery platform in Huntington's and Parkinson's diseases
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, MIT, Cambridge, MA, USA
    Biotechnol J 1:258-69. 2006
    ..In addition, we discuss new yeast-based techniques for screening candidate therapeutic compounds for Huntington's and Parkinson's diseases...
  28. ncbi request reprint Molecular genetics approaches in yeast to study amyloid diseases
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    J Mol Neurosci 23:49-60. 2004
    ..A final advantage of using yeast to study amyloid formation and toxicity is the ease and rapidity with which large-scale drug-screening efforts can be conducted in this model organism...
  29. ncbi request reprint Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease
    Jean Christophe Rochet
    Center for Neurologic Diseases, Brigham and Women s Hospital, Department of Neurology, Harvard Medical School, Cambridge, MA 02139, USA
    J Mol Neurosci 23:23-34. 2004
    ..These variants might be useful to test whether membrane binding by alpha-synuclein is necessary for neurodegeneration in transgenic animal models of PD...
  30. pmc Yeast cells provide insight into alpha-synuclein biology and pathobiology
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Science 302:1772-5. 2003
    ..This readily manipulable system provides an opportunity to dissect the molecular pathways underlying normal alpha-synuclein biology and the pathogenic consequences of its misfolding...
  31. ncbi request reprint Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein
    Stephen Willingham
    Department of Pharmacology, University of Washington, Seattle, WA 98195 7280, USA
    Science 302:1769-72. 2003
    ....